F. Delorme

608 total citations
16 papers, 497 citations indexed

About

F. Delorme is a scholar working on Oncology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, F. Delorme has authored 16 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Surgery and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in F. Delorme's work include Cancer Treatment and Pharmacology (5 papers), Oral microbiology and periodontitis research (3 papers) and Venous Thromboembolism Diagnosis and Management (3 papers). F. Delorme is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Oral microbiology and periodontitis research (3 papers) and Venous Thromboembolism Diagnosis and Management (3 papers). F. Delorme collaborates with scholars based in Canada and India. F. Delorme's co-authors include Jacques R. Leclerc, William Geerts, Louis Desjardins, F Laroche, F Jobin, W. Lofters, B. Norris, F Letendre, A. Muldal and Elizabeth A. Eisenhauer and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

F. Delorme

16 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Delorme Canada	9	200	168	152	119	65	16	497
S. Hahnfeld Germany	10	297 1.5×	199 1.2×	187 1.2×	130 1.1×	15 0.2×	14	549
Adrian Copplestone United Kingdom	8	133 0.7×	60 0.4×	128 0.8×	66 0.6×	5 0.1×	13	493
H Ljungnér Sweden	9	231 1.2×	20 0.1×	158 1.0×	126 1.1×	178 2.7×	22	566
Ali Avcı Türkiye	11	16 0.1×	85 0.5×	57 0.4×	76 0.6×	5 0.1×	22	354
Wanda M. Hinshaw United States	6	120 0.6×	40 0.2×	77 0.5×	102 0.9×	66 1.0×	9	335
Daniel L. Dennis United States	9	77 0.4×	55 0.3×	30 0.2×	118 1.0×	14 0.2×	13	357
Cliffton Ee New Zealand	14	37 0.2×	78 0.5×	48 0.3×	148 1.2×	41 0.6×	31	409
Joanna Rupa‐Matysek Poland	11	131 0.7×	62 0.4×	96 0.6×	38 0.3×	13 0.2×	43	392
Selma Yazıcı Türkiye	9	37 0.2×	209 1.2×	38 0.3×	65 0.5×	4 0.1×	16	447
M. Kiechle-Bahat Germany	6	35 0.2×	48 0.3×	38 0.3×	78 0.7×	71 1.1×	11	347

Countries citing papers authored by F. Delorme

Since Specialization

Citations

This map shows the geographic impact of F. Delorme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Delorme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Delorme more than expected).

Fields of papers citing papers by F. Delorme

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Delorme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Delorme. The network helps show where F. Delorme may publish in the future.

Co-authorship network of co-authors of F. Delorme

This figure shows the co-authorship network connecting the top 25 collaborators of F. Delorme. A scholar is included among the top collaborators of F. Delorme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Delorme. F. Delorme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Latreille, Jean, Karen A. Gelmon, Vera Hirsh, et al.. (1998). Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Investigational New Drugs. 16(3). 265–270. 15 indexed citations

Nabholtz, J.-M., John R. Mackey, Alexander Paterson, et al.. (1997). Taxotere™ (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC). European Journal of Cancer. 33. S146–S146. 4 indexed citations

Nabholtz, J.-M., Michael Smylie, John R. Mackey, et al.. (1997). Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.. PubMed. 11(6 Suppl 6). 25–41. 24 indexed citations

Nabholtz, J.-M., John R. Mackey, Michael Smylie, et al.. (1997). P953. Phase II study of taxotere® (Docetaxel, D), Doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC). The Breast. 6(5). 343–344. 5 indexed citations

Leclerc, Jacques R., William Geerts, Louis Desjardins, et al.. (1996). Prevention of Venous Thromboembolism after Knee Arthroplasty. Annals of Internal Medicine. 25 indexed citations

Eisenhauer, Elizabeth A., F Letendre, W. Lofters, et al.. (1996). Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.. Journal of Clinical Oncology. 14(2). 422–428. 137 indexed citations

Tardif, Jean-Claude, et al.. (1996). Angiosarcomas of the interatrial septum mimicking atrial myxomas. Journal of the American Society of Echocardiography. 9(2). 209–212. 5 indexed citations

Leclerc, Jacques R., William Geerts, Louis Desjardins, et al.. (1992). Prevention of Deep Vein Thrombosis after Major Knee Surgery - A Randomized, Double-Blind Trial Comparing a Low Molecular Weight Heparin Fragment (Enoxaparin) to Placebo. Thrombosis and Haemostasis. 67(4). 417–423. 178 indexed citations

Leclerc, Jacques, et al.. (1992). The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery. British Journal of Haematology. 82(2). 391–399. 15 indexed citations

10.

Chan, E. C. S., et al.. (1989). In vitro susceptibilities of oral bacterial isolates to spiramycin. Antimicrobial Agents and Chemotherapy. 33(11). 2016–2018. 6 indexed citations

11.

Bourgouin, Jean, et al.. (1989). Effects of Adjunctive Treatment of Periodontitis With Tetracycline and Spiramycin. Journal of Periodontology. 60(10). 533–539. 47 indexed citations

12.

Chan, E. C. S., et al.. (1988). Comparison of spiramycin and tetracycline used adjunctively in the treatment of advanced chronic periodontitis. Journal of Antimicrobial Chemotherapy. 22(Supplement_B). 171–177. 14 indexed citations

13.

Lagueux, Jean, et al.. (1984). Daunorubicin-albumin copolymer targeting to leukemic cells in vitro and in vivo.. PubMed. 11(4 Suppl 3). 59–63. 5 indexed citations

14.

Delorme, F., et al.. (1984). Chemotherapy with daunorubicin-anti-CEA conjugates in human colon adenocarcinoma grafted in nude mice.. PubMed. 11(4 Suppl 3). 56–8. 2 indexed citations

15.

Halal, Fahed, et al.. (1980). Renal hypodysplasia and unilateral ovarian agenesis in the Penta‐X syndrome. American Journal of Medical Genetics. 6(2). 153–162. 13 indexed citations

16.

Delorme, F., et al.. (1970). [Dissecting aneurysm and rupture of the aorto secondary to giant-cell aortitis. Case report and review of the literature].. PubMed. 99(9). 1621–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact